Search
Pancrelipase lipase
go.drugbank.com/drugs/DB13147ApprovedInvestigational[L2509] The pancrelipase lipase is an enzyme secreted by the pancreas that is responsible for the hydrolysis of dietary fat molecules in the human digestive system. … Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands.
Products: Formula C & ELenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalzone lymphoma in selected patients. … [A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal
Prademagene zamikeracel
go.drugbank.com/drugs/DB17895ApprovedInvestigational[A273833,A273838] Patient cells are then transduced ex vivo with a replication-incompetent retroviral vector (RVV) containing the full-length COL7A1 gene, resulting in cells that express functional collagen … [L53013] It was granted an Orphan Drug designation by the EMA.[A273833]
Synonyms: EB 101, EB-101Categories: Complex MixturesBetibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigationalBetibeglogene autotemcel is an autologous gene therapy that adds functional copies of the β-globin gene (β<sup>A-T87Q</sup>-globin) to hematopoietic stem cells in order to treat β-thalassemia. … The use of betibeglogene autotemcel is more effective in patients with β-thalassemia with residual β-globin synthesis (non-β<sup>0</sup>/β<sup>0</sup> genotype) compared to those with no detectable β-globin
Categories: Complex MixturesTafamidis
go.drugbank.com/drugs/DB11644ApprovedInvestigational[A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval on 3 May 2019.[L11280]
Lanreotide
go.drugbank.com/drugs/DB06791ApprovedInvestigationalIt is approved in several countries worldwide, including the United Kingdom, Australia, and Canada. Lanreotide was first approved for use in the United States by the FDA on August 30, 2007. … Lanreotide is a drug employed in the management of acromegaly (a hormonal condition caused by excess growth hormone) in addition to symptoms caused by neuroendocrine tumors, especially carcinoid syndrome
Products: Mytolac 60 mg Injektionslösung in einer Fertigspritze, Mytolac 90 mg Injektionslösung in einer FertigspritzeSofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalNotably, sofosbuvir has come under intense scrutiny since its release to market in 2013. With the price per pill set at $1000, a 12-week treatment can cost upwards of $84,000 per patient [A19636]. … Its use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627].
Olopatadine
go.drugbank.com/drugs/DB00768ApprovedAn ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. … [A179809] Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations
Picolinic acid
go.drugbank.com/drugs/DB05483ExperimentalPicolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses. … It acts as an anti-infective and immunomodulator and is produced in approximately 25-50 mg quantities by the body on a daily basis through the breakdown of tryptophan.
Categories: Compounds used in a research, industrial, or household settingLabetalol
go.drugbank.com/drugs/DB00598ApprovedInvestigational[L7730] Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984.[L7724]
Products: Labetalol HCl in Dextrose, Labetalol HCl in Sodium Chloride